TC BioPharm (Holdings) plc Annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in GBP from 2022 to 2023

Taxonomy & unit
us-gaap: GBP
Description
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Summary
TC BioPharm (Holdings) plc quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from 2022 to 2023.
  • TC BioPharm (Holdings) plc Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending March 31, 2024 was -£3.43M, a 232% decline year-over-year.
  • TC BioPharm (Holdings) plc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was -£7M, a 131% decline from 2022.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (GBP)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -7M -3.96M -131% Jan 1, 2023 Dec 31, 2023 10-K 2024-04-01
2022 -3.03M Jan 1, 2022 Dec 31, 2022 10-K 2024-04-01
* An asterisk sign (*) next to the value indicates that the value is likely invalid.